UCB jumps over 4% after Morgan Stanley upgrades to “overweight”

UCB S.A. shares gained over 4% after Morgan Stanley upgraded the stock to "overweight," raising its price target to €220 on strong growth prospects, particularly for its key immunology drug Bimzelx. The brokerage forecasts Bimzelx sales reaching €1.5 billion by FY2025, significantly above consensus, with peak sales potentially hitting €6-7 billion, driven by new indications and strong U.S. market access. Morgan Stanley projects UCB's EBITDA to grow at a 22% CAGR from 2025-2028, nearly double its peers, and views competitive threats in the expanding HS market as overstated, positioning UCB at an inflection point with substantial upside.

Analysis

UCB S.A. shares experienced a significant uptick of over 4% following a strategic upgrade from Morgan Stanley to “overweight,” with a revised price target of €220 from €200. The core driver for this bullish revision is the strong growth outlook for UCB's key immunology drug, Bimzelx. Morgan Stanley's sales forecast for Bimzelx is €1.5 billion for fiscal year 2025, substantially higher than the consensus estimate of €1.36 billion, with potential peak sales reaching €6-7 billion. This optimism is predicated on strong U.S. script trends, improved market access, and the drug's expansion into new indications such as psoriatic arthritis and hidradenitis suppurativa (HS). Financially, the brokerage projects a robust 22% compound annual growth rate for UCB's EBITDA from 2025 to 2028, nearly doubling the rate of sector peers. While acknowledging competitive risks from rivals like MoonLake's sonelokimab in the HS market, Morgan Stanley views this threat as overstated, citing the market's large potential size ($9 billion) and differences in trial designs. The firm concludes that UCB is at an inflection point, with its premium valuation justified by a superior growth trajectory and an underappreciated pipeline, which includes promising atopic dermatitis assets with data expected later this year.

Key Decisions for Investors

• Given the strong analyst conviction and detailed growth thesis, investors could view the stock's recent pullback as an attractive entry point, aligning with the upgraded 'overweight' rating.
• Monitor the quarterly sales figures for Bimzelx closely, as performance exceeding the consensus forecast of €1.36 billion for FY2025 would serve as a primary validation of the bull case.
• Keep a close watch on the Phase 3 trial results for MoonLake's sonelokimab and any shifts in U.S. healthcare policy, as these are the most significant identified risks to UCB's market dominance and growth projections.
• Upcoming data releases for UCB's early-stage atopic dermatitis assets later this year represent a key potential catalyst and should be monitored for signs of pipeline diversification and long-term value creation.